Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Specific Use Result Survey of PRALIA 60 mg Subcutaneous Injection Syringe in Rheumatoid Arthritis
jRCT1080223691Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of denosumab in rheumatoid arthritis (RA), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Long-term safety of denosumab in routine clinical practice and Effectiveness in reducing progression of bone erosion. Started Oct 2017; status: completed.
02
Drugs
denosumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT1080223691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223691.